When was Neoantigen founded?

Neoantigen was founded in 2016 and raised its 1st funding round 5 years after it was founded.

Where is Neoantigen located?

Neoantigen is headquartered in Hangzhou, China.

Who is the current CEO of Neoantigen?

Fan Mo of Neoantigen. They have also founded 1 company.

Is Neoantigen a funded company?

Neoantigen is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Sep 17, 2021.

When was the latest funding round of Neoantigen?

Neoantigen's latest funding was a $***** Seed round on Sep 17, 2021, with participation from 2 investors.

Where does Neoantigen rank among its competitors?

Neoantigen ranks 2296th amongst 3546 active competitors, of which 1214 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Neoantigen?

Neoantigen's top competitors include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Neoantigen - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of immunotherapeutics for treating cancer. The products include iNeo-Vac-P01 an Individualized neoplastic antigen peptide vaccine and iNeo-Vac-T01 is a tumor neonatal antigen-specific autoimmune cell product. The compound's design contains a variety of antigens and uses a subcutaneous injection to stimulate the immune response of CD8 positive and CD4 positive T cells.

Website: neoantigen.cn
Email ID: *****@neoantigen.cn
Phone Number: +86 **********

Key Metrics

Founded Year

2016

Location

Hangzhou, China

Stage

Seed

Latest Funding Round

Seed, Sep 17, 2021, $*****

Investors

Betta Pharmaceuticals & 2 more

Ranked

2296^th among 3546 active competitors

Similar Companies

Jazz Pharmaceuticals & 3433 more

View Neoantigen's full profile

Neoantigen has raised funding over 1 round. Its latest funding round was a Seed round on Sep 17, 2021 for $*****. 2 investors participated in its latest round. Neoantigen has 3 institutional investors.

Here is the list of recent funding rounds of Neoantigen:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 17, 2021	2079447	Seed	3127663	2750892	2735440	6960239

Access funding benchmarks and valuations. Sign up today!

View details of Neoantigen's funding rounds and investors

The founders of Neoantigen are Fan Mo and Chen Shuqing. Fan Mo is the CEO of Neoantigen.

Here are the details of Neoantigen's key team members:

Fan Mo: Co-Founder & CEO of Neoantigen.
Chen Shuqing: Co-Founder of Neoantigen.

View details of Neoantigen's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neoantigen include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Here is the list of Top 10 competitors of Neoantigen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
9th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
10th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
2296th	Neoantigen 2016, Hangzhou (China), Seed	Developer of immuno therapeutics for treating cancer	-	Fortune Capital, Betta Pharmaceuticals & 1 others	27/100